Allergy

Author Guidelines

NIH Public Access Mandate
For those interested in the Wiley-Blackwell policy on the NIH Public Access Mandate, please visit our policy statement

Author Guidelines

Allergy is now only accepting manuscripts electronically via an online submission site, Manuscript Central. The use of this system will speed the time to decision, improve accuracy, enable immediate distribution and allow authors to track their own manuscripts. Complete instructions for preparing and submitting manuscripts online are provided at the Manuscript Central submission site. If you need assistance, please phone 1 434 817 2040 x167 or e-mail ts.mcsupport@thomson.com.

Articles must be written in correct scientific English suitable for publication. Although articles are subject to review and editing, the journal does not hold itself responsible for all statements made by contributors. The first page should contain only the title of the article, the authors' names and institutions, and the full postal address of the author to whom communications and proofs are to be sent, and from whom offprints are to be requested.

Authors submitting a paper do so on the understanding that the manuscript has been read and approved by all authors and that all authors agree to the submission of the manuscript to the Journal. It is a requirement that the corresponding author submits a short description of each individual's contribution to the research and its publication. Contributions will be published under a separate heading ‘Authors Contributions’. Upon submission of a manuscript all co-authors should also be registered with correct e-mail addresses. Allergy adheres to the definition of authorship set up by The International Committee of Medical Journal Editors (ICMJE). According to the ICMJE authorship criteria should be based on 1) substantial contributions to conception and design of, or acquisition of data or analysis and interpretation of data, 2) drafting the article or revising it critically for important intellectual content and 3) final approval of the version to be published. Authors should meet conditions 1, 2 and 3. Contributors who do not qualify as authors should be mentioned under ‘Acknowledgements’.

Authors are required to disclose any potential conflict of interest. These include financial interests (for example patent, ownership, stock ownership, consultancies, speaker's fee,) or provision of study materials by their manufacturer for free or at a discount from current rates. Author's conflict of interest (or information specifying the absence of conflicts of interest) will be published under a separate heading entitled ‘Conflict of Interest Statement’. See here for ICMJE Form for Disclosure of Potential Conflicts of Interest.

We strongly recommend that each manuscript is accompanied by a cover letter, in which authors clearly describe why their work is novel and important and why it should be published in Allergy.

Authors submitting a paper do so on the understanding that the work has not been published before, is not being considered for publication elsewhere, and has been read and approved by all authors. The submission of the manuscript by the authors means that they automatically agree to licence exclusive copyright to Blackwell Munksgaard if and when the manuscript is accepted for publication. Copyright licensing is a condition of publication and papers will not be passed to the publisher for production unless copyright has been licensed. The work shall not be published elsewhere in any language without the written consent of the publisher. The articles published in this journal are protected by copyright, which covers translation rights and the exclusive right to reproduce and distribute all of the articles printed in the journal. No material published in the journal may be stored on microfilm or videocassettes or in electronic databases or retrieval systems without the written permission of the publisher. Upon acceptance, the corresponding author should sign on behalf of co-authors a Copyright Transfer Agreement (Please note: The Copyright Transfer Agreement asks you to note who publishes Allergy. In that field please write "Wiley-Blackwell on behalf of John Wiley & Sons A/S") and return it to:

Penny Smith
Wiley-Blackwell
John Wiley & Sons, Inc.
9600 Garsington Road
OX4 2DQ Oxford
UK
Fax: +44 131 226 3803
Email: all@wiley.com

Allergy employs a plagiarism detection system. By submitting your manuscript to this journal you accept that your manuscript may be screened for plagiarism against previously published works.

OnlineOpen is available to authors of primary research articles who wish to make their article available to non-subscribers on publication, or whose funding agency requires grantees to archive the final version of their article. With OnlineOpen, the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made available to non-subscribers upon publication via Wiley Online Library, as well as deposited in the funding agency's preferred archive. For the full list of terms and conditions, see http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms.

Any authors wishing to send their paper OnlineOpen will be required to complete the payment form available from our website.

Prior to acceptance there is no requirement to inform an Editorial Office that you intend to publish your paper OnlineOpen if you do not wish to. All OnlineOpen articles are treated in the same way as any other article. They go through the journal's standard peer-review process and will be accepted or rejected based on their own merit.

**Important changes for papers submitted after 06/12/2010**

I. Editorials
Editorials are usually commissioned by the Editorial board. Submissions can be considered after consultation with the Editors-in-Chief only.

Text is strictly limited to
• less than 1,500 words not including abstracts, figure legends and references (please supply a word count)
• up to 20 references in the Journal's style (if more, justification should be provided)
• references should be stated
• up to 2 figures and/or tables (total)

The number of authors should be limited to 5 (if more, justification should be provided)

Title
• should be concise and descriptive (not declarative)
• length less than 100 characters

Short title of less than 50 characters

Key words: up to 5, listed in alphabetical order

II. Position papers

Text is limited to:
• less than 4,500 words not including abstracts, figure legends and references (please supply a word count)
• up to 75 references in the Journal's style (if more, justification should be provided)
• figures and tables are important in position papers and up to 10 figures and/or tables (total) can be included in the text

Title
• should be concise and descriptive
• length less than 100 characters

The number of authors should be limited to 8 (if more, justification should be provided)

Short title of less than 50 characters

Abstract: 200 words unstructured summary

Key words: up to 5, listed in alphabetical order  

III. Review articles
Reviews should present an update of the most recent developments in a particular field of clinical allergy and immunologic research. We encourage the submission of high quality color pictures and cartoons which may be selected for the cover of the issue.

Text:
• less than 4,500 words not including abstract, figure legends and references (please supply a word count)
• up to 75 references in the Journal's style (if more, justification should be provided)
• figures and tables are important in review papers and up to 10 figures and/or tables (total) can be included in the text

Title
• should be concise and descriptive
• length less than 100 characters

The number of authors should be limited to 5 (if more, justification should be provided)

Short title of less than 50 characters

Abstract: 200 words unstructured summary

Key words: up to 5, listed in alphabetical order

IV. Original articles
We welcome high quality original publications dealing with innovative aspects of clinical allergy and immunologic research.

A. General information concerning the format of the manuscripts for all original papers

Title
• should be concise and informative (ex: Allergen X is a major factor in asthma) but not descriptive (ex: Role of allergen X in asthma)
• length less than 100 characters
• If experiments have been performed in animal models, the species should be specified in the title (ex: Role of allergen X in a murine asthma model)

Short title of less than 50 characters

Abstract: 250 words structured as follows:
• background (including the aims of the study)
• methods. If space is short, report only the primary outcomes
• results. For animal models, specify the species
• conclusions

Key words: up to 5, listed in alphabetical order

Text:
The text is limited to:
• less than 2,500 words not including abstract, figure legends and references (please supply a word count)
• up to 35 references in the Journal's style (see below)
• up to 6 figures and/or tables (total) If longer, in the cover letter, reasons for increase in length, figure or table number or reference number should be stated

Note: Original articles are limited to 5 printed pages in total. Authors must pay GBP 80 for each additional page.


B. Special considerations for manuscripts dealing with particular fields.
B.1. Epidemiological Studies: For reports of epidemiological studies, authors should consult the STROBE initiative.

B.2. Clinical Trials: Authors of trials should adhere to the CONSORT reporting guidelines appropriate to their trial design.

B.3. Genetic, genomic and proteomic studies: Authors of genetic association studies are strongly encouraged to consult the recommendations issued by the STREGA initiative. Reports of microarray experiments should conform to the MIAME guidelines, in an appropriate publicly accessible database.

B.4. Manuscripts dealing with recombinant allergens will only be considered for external review if they:
• describe a new allergen or a class of new allergenic molecules; ii) show the clinical relevance of the allergens;
• describe new technological approaches for cloning, production and/or characterization of allergens;
• the sequence has been submitted, accepted and assigned with an official name by the I.U.I.S. Allergen Nomenclature Sub-committee
• provides a relevant progress with respect to the state of the art of the research in the field of molecular allergy;
• manuscripts, which do not fulfil the requirements, but which contain interesting information of potential interest for the readers of Allergy, might be considered for publication as a short communication.

V. Brief communications
Brief communications are peer-reviewed original articles with an important new key message. Please note that single case reports will not be considered for publication.

Title
• should be concise and informative (ex: Allergen X is a major factor in asthma) but not descriptive (ex: Role of allergen X in asthma)
• length less than 100 characters
• If experiments have been performed in animal models, the species should be specified in the title (ex: Role of allergen X in a murine asthma model)

Short title of less than 50 characters

Abstract: 150 words unstructured summary

Key words: up to 5, listed in alphabetical order

Text:
The text is limited to:
• less than 1,000 words not including abstract, figure legends and references (please supply a word count) • up to 15 references of the Journal's style (see below)
• up to 2 figures and/or tables (total) Brief communications are limited to 2 printed pages. Authors must pay GBP 80 for each added page The special considerations mentioned above (original articles) are also valid for brief communications

VI. News and commentaries
Short manuscripts dealing with particular new developments and concepts are welcome in this section.

Text is strictly limited to
• less than 1,500 words not including abstracts, figure legends and references (please supply a word count)
• up to 20 references in the Journal's style (if more, justification should be provided)
• references should be stated • up to 2 figures and/or tables (total) The number of authors should be limited to 5 (if more, justification should be provided)

Title
• should be concise and descriptive (not declarative)
• length less than 100 characters

Short title of less than 50 characters

Key words: up to 5, listed in alphabetical order  

VII. Correspondence
Letters to the Editor are welcome only if they refer to an original article published in Allergy. The letter should be sent as an electronic file to the desk of the Editor within two months after publication of the article.

The text is strictly limited to
• less than 600 words (please supply a word count)
• up to 6 references in the Journal's style
• 1 figure and/or table

Procedure: The letter will be sent to the author of the article, who will have 6 weeks to answer. After the reply, no further correspondence will be accepted. Letters are not peer reviewed.

References - The style of citations and references must conform to that of the 'Uniform requirements for manuscripts submitted to biomedical journals' as stated by the International Committee of Medical Journal Editors (BMJ 1991;302:338-341). References should be numbered consecutively in the order in which they are first mentioned in the text. References are to be indicated in text, tables, and legends by Arabic numerals in parentheses. All references cited, and only these, are to appear consecutively in the list at the end of the paper. List all authors when 6 or fewer; when 7 or more, list the first 6 and add et al. Authors should consult a recent issue of Allergy and note the following examples:

Journals: Novak N, Bieber T, Allam JP. Immunological mechanisms of sublingual allergen-specific immunotherapy. Allergy 2011;66:733-739.
Books: Czarnetzki BM. Urticaria. Berlin: Springer, 1986.
Chapter in a book: Simon D, Simon HU. Eosinophils. In: Barnes PJ, Drazen JM, Rennard SI, Thomson NC, editoris. Asthma and COPD. San Diego, Burlington, London, Amseterdam: Elsevier Ltd., Academic Press, 2009; 145-156.

References in Articles - We recommend the use of a tool such as EndNote or Reference Manager for reference management and formatting. The EndNote reference style can be downloaded here. Reference Manager reference styles can be searched for here

Illustrations:
Colour illustrations will be accepted if considered necessary by the editor but must be paid for by the author. Manuscripts might be re-reviewed if authors decline to pay for the colour figures. Authors required to pay for colour must complete a Color Work Agreement Form. If you wish to publish images in colour, then as soon as your paper is accepted please send the completed Colour Work Agreement Form to:

Penny Smith
Wiley-Blackwell
John Wiley & Sons, Inc.
9600 Garsington Road
OX4 2DQ Oxford
UK
Fax: +44 131 226 3803
Email: all@wiley.com

Line artwork (such as graphs) should be submtited as EPS files, or TIFF files with a minimum resolution of 800dpi. Other artwork (such as photographs) should be submitted as 250-300 dpi TIFF files. Information on creating EPS files from Microsoft Windows, Powerpoint, Excel and Apple Mac is available from the Author Services website.

Tables - The layout must allow the tables to be read in the same direction as the text. They should be numbered consecutively with Arabic numerals, each typed on a separate page, due regard being paid to the proportion of the printed pages, and provided with self-explanatory legends.

Abbreviations and symbols - Only abbreviations and symbols that are generally accepted should be used. Unfamiliar ones must be defined when first used.

Revised manuscripts - Revised manuscripts must include the following items: • A Responses to Comments that includes point-by-point responses to the comments made by the Reviewers, Editor, and Editorial Office labeled as 'COMMENT' and 'RESPONSE' for each item. • A Marked Manuscript. Any text that was not part of the original manuscript but has now been added, underline formatting should be applied; to any text that was part of the original manuscript but has now been deleted, strikethrough formatting should be applied. Changes made on Figures and Tables should be clearly visible and provided as separate files labeled as 'Figure x Marked' and 'Table x Marked'. Line numbering should be used in the Marked Manuscript and numbers mentioned in the response to the comments. • An Unmarked Manuscript. The Unmarked Manuscript should be your revised manuscript just as you intend it for publication (if it is accepted). Any table and figure that is to be part of your revised manuscript should be provided as a separate file (e.g., 'Figure x-Unmarked' or 'Table x- Unmarked'). Line numbering need not be used in the Unmarked Manuscript too.

Proofs - The corresponding author will receive an email alert containing a link to a web site. A working e-mail address must therefore be provided for the corresponding author. The proof can be downloaded as a PDF (portable document format) file from this site. Acrobat Reader will be required in order to read this file. This software can be downloaded (free of charge) here.

This will enable the file to be opened, read on screen and printed out in order for any corrections to be added. Further instructions will be sent with the proof. Hard copy proofs will be posted if no e-mail address is available. Excessive changes made by the author in the proofs, excluding typesetting errors, will be charged separately.

Early View - Allergy is covered by Wiley-Blackwell's Early View service. Early View articles are complete full-text articles published online in advance of their publication in a printed issue. They have been fully reviewed, revised and edited for publication, and the authors' final corrections incorporated. Authors cannot make changes to their articles after online publication. Early View articles are given a Digital Object Identifier (DOI), which allows each article to be cited and tracked before it is allocated to an issue. After print publication, the DOI remains valid and can continue to be used to cite and access the articles.

Offprints - Offprints without covers can be ordered on the form accompanying the proofs.

Author Services - Author Services enables authors to track their article - once it has been accepted - through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated e-mails at key stages of production. The author will receive an e-mail with a unique link that enables them to register and have their article automatically added to the system. Please ensure that a complete e-mail address is provided when submitting the manuscript. Visit http://authorservices.wiley.com/bauthor/ for more details on online production tracking and for a wealth of resources including FAQs and tips on article preparation, submission and more.

Supplements - These are papers exceeding 20 printed pages whose publication is paid for entirely by the author. Although supplements must be accepted by the editorial office, the journal does not hold itself responsible for all statements made by contributors. After acceptance, supplements do not undergo editorial revision, but should be as similar as possible in style (especially citation style) and format to original articles. It is Wiley´s Blackwell policy to acknowledge in supplements any major sponsorship. Supplements are not peer reviewed.

Allergy collaborates with Wiley’s Open Access Journal, Immunity, Inflammation and Disease, to enable rapid publication of good quality research that we are unable to accept for publication in Allergy. Authors will be offered the option of having the paper, along with any related peer reviews, automatically transferred for consideration by the Editor of Immunity, Inflammation and Disease. Authors will not need to reformat or rewrite their manuscript at this stage, and publication decisions will be made a short time after the transfer takes place. The Editor of Immunity, Inflammation and Disease will accept submissions that report well-conducted research which reaches the standard acceptable for publication. Immunity, Inflammation and Disease is a Wiley Open Access journal and article publication fees apply. For more information please go to www.immunityinflammationdisease.com.